Matches in SemOpenAlex for { <https://semopenalex.org/work/W2029837010> ?p ?o ?g. }
- W2029837010 endingPage "151" @default.
- W2029837010 startingPage "141" @default.
- W2029837010 abstract "Inadequacies of the current pharmacotherapies to treat Parkinson’s disease (PD) have prompted efforts to identify novel drug targets. The adenosine A2A receptor is one such target. Antagonists of this receptor (A2A antagonists) are considered promising agents for the symptomatic treatment of PD. Evidence suggests that A2A antagonists may also have neuroprotective properties that may prevent the development of the dyskinesia that often complicates levodopa treatment. Because the therapeutic benefits of A2A antagonists are additive to that of dopamine replacement therapy, it may be possible to reduce the dose of the dopaminergic drugs and therefore the occurrence of side effects. Inhibitors of monoamine oxidase (MAO)-B also are considered useful tools for the treatment of PD. When used in combination with levodopa, inhibitors of MAO-B may enhance the elevation of dopamine levels after levodopa treatment, particularly when used in early stages of the disease when dopamine production may not be so severely compromised. Furthermore, MAO-B inhibitors may also possess neuroprotective properties in part by reducing the damaging effect of dopamine turnover in the brain. These effects of MAO-B inhibitors are especially relevant when considering that the brain shows an age-related increase in MAO-B activity. Based on these observations, dual-target-directed drugs, compounds that inhibit MAO-B and antagonize A2A receptors, may have value in the management of PD. This review summarizes recent efforts to develop such dual-acting drugs using caffeine as the lead compound." @default.
- W2029837010 created "2016-06-24" @default.
- W2029837010 creator A5004162414 @default.
- W2029837010 creator A5030450621 @default.
- W2029837010 creator A5041777746 @default.
- W2029837010 creator A5072159453 @default.
- W2029837010 creator A5089512969 @default.
- W2029837010 date "2009-01-01" @default.
- W2029837010 modified "2023-10-15" @default.
- W2029837010 title "Dual-target-directed drugs that block monoamine oxidase B and adenosine A2A receptors for Parkinson’s disease" @default.
- W2029837010 cites W1500797869 @default.
- W2029837010 cites W1508638897 @default.
- W2029837010 cites W1549819404 @default.
- W2029837010 cites W17131581 @default.
- W2029837010 cites W1837235659 @default.
- W2029837010 cites W1866791144 @default.
- W2029837010 cites W1968093206 @default.
- W2029837010 cites W1969617718 @default.
- W2029837010 cites W1969800514 @default.
- W2029837010 cites W1970684497 @default.
- W2029837010 cites W1972187154 @default.
- W2029837010 cites W1972420008 @default.
- W2029837010 cites W1974524303 @default.
- W2029837010 cites W1977567629 @default.
- W2029837010 cites W1981643341 @default.
- W2029837010 cites W1982467344 @default.
- W2029837010 cites W1982686544 @default.
- W2029837010 cites W1982734210 @default.
- W2029837010 cites W1983585951 @default.
- W2029837010 cites W1983818310 @default.
- W2029837010 cites W1984424527 @default.
- W2029837010 cites W1985949521 @default.
- W2029837010 cites W1987380827 @default.
- W2029837010 cites W1988824288 @default.
- W2029837010 cites W1992812982 @default.
- W2029837010 cites W1994761764 @default.
- W2029837010 cites W2000450717 @default.
- W2029837010 cites W2002784780 @default.
- W2029837010 cites W2002933217 @default.
- W2029837010 cites W2005102504 @default.
- W2029837010 cites W2010916577 @default.
- W2029837010 cites W2011475407 @default.
- W2029837010 cites W2012019301 @default.
- W2029837010 cites W2012516949 @default.
- W2029837010 cites W2013482285 @default.
- W2029837010 cites W2016873483 @default.
- W2029837010 cites W2017987961 @default.
- W2029837010 cites W2018019777 @default.
- W2029837010 cites W2020219354 @default.
- W2029837010 cites W2021374461 @default.
- W2029837010 cites W2023211111 @default.
- W2029837010 cites W2024770800 @default.
- W2029837010 cites W2026475932 @default.
- W2029837010 cites W2028285705 @default.
- W2029837010 cites W2030108063 @default.
- W2029837010 cites W2030257205 @default.
- W2029837010 cites W2031325099 @default.
- W2029837010 cites W2032352955 @default.
- W2029837010 cites W2032369231 @default.
- W2029837010 cites W2034588648 @default.
- W2029837010 cites W2037039276 @default.
- W2029837010 cites W2037168299 @default.
- W2029837010 cites W2039197913 @default.
- W2029837010 cites W2040410772 @default.
- W2029837010 cites W2042386533 @default.
- W2029837010 cites W2045678127 @default.
- W2029837010 cites W2045731233 @default.
- W2029837010 cites W2046159507 @default.
- W2029837010 cites W2046204255 @default.
- W2029837010 cites W2049123226 @default.
- W2029837010 cites W2053650795 @default.
- W2029837010 cites W2054454772 @default.
- W2029837010 cites W2054466279 @default.
- W2029837010 cites W2058495554 @default.
- W2029837010 cites W2062214351 @default.
- W2029837010 cites W2064049435 @default.
- W2029837010 cites W2065648608 @default.
- W2029837010 cites W2068009676 @default.
- W2029837010 cites W2069885465 @default.
- W2029837010 cites W2073561633 @default.
- W2029837010 cites W2075621586 @default.
- W2029837010 cites W2076097603 @default.
- W2029837010 cites W2077868413 @default.
- W2029837010 cites W2078799505 @default.
- W2029837010 cites W2083496399 @default.
- W2029837010 cites W2083868750 @default.
- W2029837010 cites W2084255205 @default.
- W2029837010 cites W2086071289 @default.
- W2029837010 cites W2086208850 @default.
- W2029837010 cites W2088277236 @default.
- W2029837010 cites W2088619016 @default.
- W2029837010 cites W2090751730 @default.
- W2029837010 cites W2091818830 @default.
- W2029837010 cites W2092666379 @default.
- W2029837010 cites W2093689732 @default.
- W2029837010 cites W2094423289 @default.
- W2029837010 cites W2103120760 @default.
- W2029837010 cites W2107560196 @default.